This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Authoring team

Treatment for Guillain-Barre syndrome is supportive. Early tracheostomy is indicated if there is progressive bulbar and respiratory weakness. The latter may be monitored with serial peak flow measurements.

Severe hypotension due to autonomic disturbance may require pressor drugs, especially in the elderly.

Specific treatment for Guillain-Barre syndrome consists of high-dose intravenous immunoglobulin (IvIg) or plasma exchange

  • both treatments have been shown to decrease recovery times if instituted early in the course of the disease
  • IvIg is favoured by many as it is easier to administer and has fewer complications than plasma exchange (e.g. sepsis) (1)

There is no role for the use of steroids.

Reference:

  • (1) Ghazi AH, Hirsch N. Neuromuscular disorders: relevance to anaesthesia and intensive care Anaesthesia & Intensive Care Medicine 2008; 9 (6): 237-239

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.